AI assistant
GALECTIN THERAPEUTICS INC — Director's Dealing 2016
Nov 15, 2016
33422_dirs_2016-11-15_95a3e5d2-c6e8-4c74-b4b4-71a93bb5e7b3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2016-11-10
Reporting Person: 10X Fund, L.P. (10% Owner)
Reporting Person: 10X Capital Management, LLC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-11-10 | Common Stock | J | 9663 | $0.78 | Disposed | 3186452 | Direct |
| 2016-11-10 | Common Stock | J | 17096 | $0.78 | Disposed | 3169356 | Direct |
Footnotes
F1: Distributed as an in-kind distribution to a withdrawing limited partner in 10X Fund, LP.
F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.